Pierce Jamieson

Pierce Jamieson is a Research Associate at ARK Investment Management LLC, where he contributes to the firm’s research on disruptive innovation and emerging technologies. He is based in Dallas, Texas, and has been with ARK since July 2021. His work is cited in ARK’s annual Big Ideas reports, and he is specifically noted for his focus on the Genomic Revolution strategy, covering synthetic biology, artificial intelligence, and automation in drug discovery, as well as precision therapies. His research helps inform ARK’s investment theses in these high-growth, technology-driven sectors.

Prior to joining ARK, Jamieson was a Partner at Phobos Capital Management, where he was involved in investment strategy and portfolio management. He also served as a Graduate Student Researcher at Texas A&M University, further developing his expertise in molecular biology and the intersection of science and technology. His background combines practical investment experience with deep scientific research, allowing him to bridge the gap between technical innovation and financial analysis.

Jamieson holds a Bachelor of Science in Biology and a degree in Molecular Biology from Texas A&M University. He also earned a Doctor of Philosophy in Philosophy from Texas A&M, demonstrating a multidisciplinary approach to complex problem-solving. His unique blend of scientific training and investment acumen has contributed to ARK’s thought leadership in precision therapies and the broader field of genomic innovation, helping to shape the firm’s forward-looking investment strategies.